The Quvium product is a small electronic, non-invasive, “always-on”, sensory device with in-built analytical software. The wearable distress monitor can be provided in several formats, such as a pin or a pendant. The unit is both light and durable and has been particularly designed to provide the necessary reliability, precision and accuracy. The system is well differentiated from current market competitors and has a superior profile in areas such as dimension, convenience, ease of use, early indication of severe event and costs. Quvium offers the only solution that constantly monitors a patient’s cough profile and sends alerts 24/7 to permit effective intervention. An asthma sufferer starts to cough immediately following insult (such as pollen or exercise) and maximum lung airway injury. Cough frequency is a highly reliable, leading indicator for an imminent asthma attack. Quvium has designed a small, wearable cough button that detects this frequency and sends a signal when the frequency indicates that an attack is pending. Quvium then sends alert messages to the patient and to the appropriate caregivers to intervene (usually by using a rescue inhaler) to prevent the attack and any A&E visit. Quvium involves the entire care community: Asthma and COPD tend to affect the very young and old, both populations that ignore all but the most critical and painful symptoms are also largely uncommunicative about their condition and they often require support in managing their disease. Quvium is actively pursuing CE Mark approval and expects to submit the application by the end of 2015. At that point, the device will be sold and distributed initially through pharmacies such as Boots or Lloyds. After that the company will pursue MHRA approval and acceptance by the NHS. The NHS will benefit by tremendous cost savings upwards of 30% from reduced A&E visits and hospitalisations due to respiratory events. The GPs will also directly benefit from using the device as its use will prevent the GP from having to send money back for avoidable hospitalisations for respiratory events. It is anticipated that this could be at least £37,600 annually for each GP.



020 7071 3945


Throughout our site you will find links to external websites. Although we make every effort to ensure these links are accurate, up to date and relevant, we cannot take responsibility for pages maintained by external providers.